It's impossible to predict the future with precise accuracy, but we can make educated guesses about general trends. For example, equity markets will likely be up from their current levels by 2030. That's a safe bet, given historical patterns. It also offers investors the opportunity to grow their capital through the end of the decade. But just buying any old stock won't do the trick.

Let's consider two companies with what it takes to deliver excellent returns through 2030: Exact Sciences (NASDAQ: EXAS) and Novo Nordisk (NYSE: NVO). Both healthcare stocks could register compound annual growth rates of more than 12% through the next six years, allowing them to double before Jan. 1, 2030 hits. Here's why. 

Cancer is one of the leading causes of death in the U.S. Although many people have never had the disease, chances are they know someone -- a family member, friend, or neighbor -- who has. Finding better ways to fight cancer is important, and that's precisely what Exact Sciences does. The company's flagship product is called Cologuard. It is a non-invasive test for colorectal cancer that was first launched in 2014.

Continue reading

Source Fool.com